Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(n-(dicyclopropylmethyl)amino)oxazoline
2. 2-(n-(dicyclopropylmethyl)amino)oxazoline Phosphate Salt
3. Hyperium
4. Oxaminozoline
5. Rilmenidine
6. S 3341
7. S 3341 3
8. S-3341
9. S-3341-3
10. S3341
11. S33413
1. 85409-38-7
2. Rilmenidine Dihydrogen Phosphate
3. Rilmenidine (phosphate)
4. S 3341-3
5. 2-oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, Phosphate (1:1)
6. N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine;phosphoric Acid
7. 59qd64q32m
8. N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine Phosphate
9. Rilmenidinephosphate
10. Einecs 287-106-2
11. Unii-59qd64q32m
12. 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine Phosphate (1:1)
13. 2-oxazolamine, 4,5-dihydro-n-(dicyclopropylmethyl)-, Phosphate (1:1)
14. (dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium Dihydrogen Phosphate
15. Schembl1231349
16. Dtxsid50234616
17. Rilmenidine For System Suitability
18. Rilmenidine Phosphate [mi]
19. Bcp13443
20. Mfcd00875846
21. N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; Phosphoric Acid
22. Rilmenidine Hydrogen Phosphate
23. S7548
24. Rilmenidine Phosphate [mart.]
25. Akos015900521
26. N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine,phosphoric Acid
27. Rilmenidine Phosphate [who-dd]
28. Ccg-267224
29. Hy-100490b
30. As-15125
31. Cs-0020190
32. Ft-0656776
33. A14256
34. S-3341
35. 409r387
36. A841323
37. S-3341-3
38. W-104082
39. Q27261715
40. Rilmenidine Dihydrogen Phosphate [ep Monograph]
41. (5-methylpyridin-2-yl)piperidin-4-yl-aminedihydrochloride
42. 2-((dicyclopropylmethyl)amino)-2-oxazoline Phosphate
43. Dicyclopropylmethyl-(4,5-dihydrooxazol-2-yl)ammonium Phosphate
Molecular Weight | 278.24 g/mol |
---|---|
Molecular Formula | C10H19N2O5P |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 278.10315871 g/mol |
Monoisotopic Mass | 278.10315871 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 269 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
Market Place
ABOUT THIS PAGE
A Rilmenidine Phosphate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rilmenidine Phosphate, including repackagers and relabelers. The FDA regulates Rilmenidine Phosphate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rilmenidine Phosphate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rilmenidine Phosphate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rilmenidine Phosphate supplier is an individual or a company that provides Rilmenidine Phosphate active pharmaceutical ingredient (API) or Rilmenidine Phosphate finished formulations upon request. The Rilmenidine Phosphate suppliers may include Rilmenidine Phosphate API manufacturers, exporters, distributors and traders.
click here to find a list of Rilmenidine Phosphate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rilmenidine Phosphate CEP of the European Pharmacopoeia monograph is often referred to as a Rilmenidine Phosphate Certificate of Suitability (COS). The purpose of a Rilmenidine Phosphate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rilmenidine Phosphate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rilmenidine Phosphate to their clients by showing that a Rilmenidine Phosphate CEP has been issued for it. The manufacturer submits a Rilmenidine Phosphate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rilmenidine Phosphate CEP holder for the record. Additionally, the data presented in the Rilmenidine Phosphate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rilmenidine Phosphate DMF.
A Rilmenidine Phosphate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rilmenidine Phosphate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rilmenidine Phosphate suppliers with CEP (COS) on PharmaCompass.
Rilmenidine Phosphate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rilmenidine Phosphate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rilmenidine Phosphate GMP manufacturer or Rilmenidine Phosphate GMP API supplier for your needs.
A Rilmenidine Phosphate CoA (Certificate of Analysis) is a formal document that attests to Rilmenidine Phosphate's compliance with Rilmenidine Phosphate specifications and serves as a tool for batch-level quality control.
Rilmenidine Phosphate CoA mostly includes findings from lab analyses of a specific batch. For each Rilmenidine Phosphate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rilmenidine Phosphate may be tested according to a variety of international standards, such as European Pharmacopoeia (Rilmenidine Phosphate EP), Rilmenidine Phosphate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rilmenidine Phosphate USP).
LOOKING FOR A SUPPLIER?